Nurix pushes its degrader forward
The company will start its confirmatory bexobrutideg study in June.
The non-covalent BTK space expands
Hutchmed goes pivotal with HMPL-760 in B-cell lymphoma.
ASH 2025 preview – Kelonia gets a late-breaking coup
An in vivo Car-T produced a 100% response rate – in three patients.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Lilly urges degrader caution
Meanwhile, the company plays down the risk of Jaypirca’s CLL approval being rescinded.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
